Food And Drug Administration Grants Two New Label Changes To Tirosint®-Sol (Levothyroxine Sodium) Or

New FDA-approved label updates offer patients more flexible administrationPARSIPPANY, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hyp...

Related Keywords

United States ,China ,Switzerland ,Lugano ,Ticino ,Colorado ,Swiss ,Francesco Celi ,Michael Scully ,Clin Endocrinol Oxf ,Institut Biochimique ,Research Study ,Nutrition Examination ,National Health ,University Of Connecticut School Medicine ,Group Website ,Mann Lab ,Drug Administration ,Scientific Affairs ,Pharma Inc ,Commercial Operations ,Connecticut School ,Copay Savings Coupon ,Tirosint Direct ,Full Prescribing Information ,Boxed Warning ,Thyroid Epidemiology ,Clin Endocrinol ,Nutrition Examination Survey ,Med Res ,